The effects of discontinuation of vitamin K antagonists on the rate of elastin degradation

The effects of discontinuation of vitamin K antagonists on the rate of elastin degradation - VKA discontinuation and elastolysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45726

Enrollment

100

Registered

2017-06-29

Start date

2017-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elastin-degradation vitamin K deficiency

Interventions

desmosine

elastin degradation

VKAs

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: VKA users who will discontinuate VKAs

Exclusion criteria

Exclusion criteria: life expectancy

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the change in the rate of elastin degradation quantified by the plasma desmosine assay.	—

Secondary

Measure	Time frame
Secondary endpoints are the change in vitamin K status quantified by measuring plasma levels of dephosphorylated uncarboxylated (dp-uc, i.e. inactive) Matrix Gla Protein (MGP), the relation between desmosine and dp-ucMGP and differences of desmosine and dp-ucMGP levels among subjects with different polymorphisms of the vitamin K 2,3-epoxide reductase complex 1 (VKORC1) gene.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)